{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT00396149",
      "orgStudyIdInfo": {
        "id": "VO49.06 DK"
      },
      "organization": {
        "fullName": "Stallergenes Greer",
        "class": "INDUSTRY"
      },
      "briefTitle": "Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1",
      "officialTitle": "A Phase I Study to Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Higher Multi Dose Regimens to Subjects Sensitised to Birch Pollen"
    },
    "statusModule": {
      "statusVerifiedDate": "2009-04",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2006-11"
      },
      "primaryCompletionDateStruct": {
        "date": "2007-03",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2007-06",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2006-11-02",
      "studyFirstSubmitQcDate": "2006-11-02",
      "studyFirstPostDateStruct": {
        "date": "2006-11-06",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2013-06-26",
      "lastUpdatePostDateStruct": {
        "date": "2013-06-27",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "oldNameTitle": "Bruno ROBIN",
        "oldOrganization": "Stallergenes"
      },
      "leadSponsor": {
        "name": "Stallergenes Greer",
        "class": "INDUSTRY"
      },
      "collaborators": [
        {
          "name": "Quintiles, Inc.",
          "class": "INDUSTRY"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "To investigate the safety and tolerability of successive single rising doses of SLIT in subjects with allergic rhinitis and to investigate the safety and tolerability of multi high dose regimens of SLIT in subjects with allergic rhinitis."
    },
    "conditionsModule": {
      "conditions": [
        "Birch Pollen-Related Rhinoconjunctivitis",
        "Rhinitis, Allergic, Seasonal"
      ],
      "keywords": [
        "rBet v 1",
        "Birch pollen allergy",
        "Sublingual Immunotherapy"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 57,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "Placebo group",
          "interventionNames": [
            "Biological: Placebo"
          ]
        },
        {
          "label": "Active group",
          "type": "EXPERIMENTAL",
          "description": "rBet v 1 tablets",
          "interventionNames": [
            "Biological: rBet v 1"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Placebo",
          "description": "Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.",
          "armGroupLabels": [
            "Placebo"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "rBet v 1",
          "description": "Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 50 to 300 µg rBet v 1.",
          "armGroupLabels": [
            "Active group"
          ],
          "otherNames": [
            "rBet v 1.0101"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Local tolerability",
          "timeFrame": "Assessed every day over 2 weeks"
        },
        {
          "measure": "Global safety",
          "timeFrame": "Assessed every day over 2 weeks"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Immunological markers (IgE and IgG4)",
          "timeFrame": "Between selection and follow-up visit"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* written consent\n* Symptoms of birch pollen induced allergic rhinitis for at least the last 2 years.\n* Sensitisation to birch pollen as demonstrated with a positive SPT to birch pollen and specific IgE level (birch pollen and r Bet v1) of at least Class 2 at screening.\n* FEV1 at least of 80% of predicted values at screening.\n\nExclusion Criteria:\n\n* Patient who previously received desensitization treatment to birch pollen and/or other betulaceae (e.g., hazel tree, alder…) or who plan to start desensitization treatment during this study.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "60 Years",
      "stdAges": [
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Hans-Jorgen MALLING, Professor",
          "affiliation": "National University Hospital, Copenhagen",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "National University Hospital - Allergy Unit 4222",
          "city": "Copenhagen",
          "country": "Denmark",
          "geoPoint": {
            "lat": 55.67594,
            "lon": 12.56553
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "type": "RESULT",
          "citation": "L. Winther, L.K. Poulsen, B. Robin, M. Mélac, H. Malling Safety and Tolerability of Recombinant Bet v 1 (rBet v 1) Tablets in Sublingual Immunotherapy (SLIT) The Journal of Allergy and Clinical Immunology February 2009 (Vol. 123, Issue 2, Page S215)"
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D006255",
          "term": "Rhinitis, Allergic, Seasonal"
        }
      ],
      "ancestors": [
        {
          "id": "D065631",
          "term": "Rhinitis, Allergic"
        },
        {
          "id": "D012220",
          "term": "Rhinitis"
        },
        {
          "id": "D009668",
          "term": "Nose Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D012130",
          "term": "Respiratory Hypersensitivity"
        },
        {
          "id": "D010038",
          "term": "Otorhinolaryngologic Diseases"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    }
  },
  "hasResults": false
}